Paper Details

  1. Home
  2. Paper Details

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

Author: Al-FayoumiSuliman, CastilloSonia, ChakrabortiTamal, ChoudaryJasti, FrankewichRaymond, KacubaAlice, PazdurRichard, RievesDwaine, Robie-SuhKathy, ShashatyGeorge, WeissKaren

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis. The FDA granted deferasirox accelerated approval on November 2, 2005, for use in treating chronic iron overload due to transfusional hemosiderosis in patients > or =2 years of age. The sponsor must obtain clinical data demonstrating the drug's long-term safety and effectiveness.
Paper Details　
Original Abstract of the Article :
PURPOSE: This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis. EXPERIMENTAL DESIGN: The FDA reviewed findings of a controlled,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/17263129

データ提供：米国国立医学図書館（NLM）

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

This research focuses on the use of deferasirox, an oral iron chelator, to treat chronic iron overload in patients with transfusional hemosiderosis. The study examines the efficacy and safety of deferasirox compared to the existing treatment, deferoxamine. Imagine a nomad who has found a new source of water in the desert, but this water is also carrying a dangerous mineral that needs to be removed.

A New Solution for Iron Overload

The study found that deferasirox was as effective as deferoxamine in reducing liver iron concentrations in patients with transfusional hemosiderosis. This is like the nomad discovering a new method for purifying the water, making it safe for consumption.

A Closer Look at Side Effects

While deferasirox was found to be effective, the study also noted that it was associated with an increase in serum creatinine levels in some patients. This is like the nomad realizing that while the new water source is beneficial, it also comes with a potential risk that needs to be monitored.

Dr. Camel's Conclusion

This research highlights the importance of finding new and effective treatments for chronic conditions. The discovery of deferasirox offers a promising alternative for managing iron overload, but it's crucial to carefully monitor any potential side effects. It's like a nomad discovering a new source of water in the desert, but also realizing that they must be cautious about the risks it might present.

Date :
  1. Date Completed 2007-03-01
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17263129

DOI: Digital Object Identifier

169392

Related Literature

Article Analysis
・Effective treatment of iron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.